Day: January 25, 2021

Company Announcement No. 857On 29 October 2020, we initiated a share buyback programme, as described in Company Announcement No. 842 of 29 October 2020. According to the programme, the company will in the period from 29 October 2020 to 30 April 2021 purchase own shares up to a maximum value of DKK 6,000,000,000 and no more than 12,000,000 shares, corresponding to 5.22% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.As at today, DSV Panalpina A/S holds a total of 5,236,078 shares of a nominal value of DKK 1 in DSV Panalpina A/S, corresponding to 2.28% of the total number of issued shares of 230,000,000.The...

To    Nasdaq Copenhagen25 January 2021 Nykredit Realkredit A/S – New final terms for Euro Medium Term Note ProgrammeNykredit Realkredit A/S publishes final terms for an issue of SEK 550,000,000 Floating Rate Senior Non-Preferred Notes due 2023, which are issued pursuant to Nykredit Realkredit A/S’s and Nykredit Bank A/S’s €10,000,000,000 Euro Medium Term Note Programme dated 13 May 2020.The final terms dated 25 January 2021 and the EMTN Programme dated 13 May 2020 are available for download on Nykredit’s website at nykredit.com/ir.Enquiries may be addressed to Nykredit Realkredit A/S, Nicolaj Legind Jensen, Executive Vice President, Funding & Capital, tel +45 44 55 11 10, or Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.AttachmentNykredit_Realkredit_New_final_terms_for_Euro_Medium_Term_Note_...

GUERBET : Nombre d’actions et de droits de vote composant le capital de la société au 31 décembre 2020En application de l’article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les sociétés dont des actions sont admises aux négociations sur un marché réglementé publient sur leur site Internet et transmettent à l’AMF, à la fin de chaque mois, le nombre total de droits de vote et le nombre d’actions composant le capital de la société s’ils ont varié par rapport à ceux publiés antérieurement. Ces sociétés sont réputées remplir l’obligation prévue au I de l’article L. 233-8 du code de commerce.1 calculé, comme prévu au dernier alinéa de l’article 223-11 du règlement général, sur la base de l’ensemble des actions auxquelles sont attachés...

København Ø, Jan. 25, 2021 (GLOBE NEWSWIRE) —Den 21. januar 2021 blev der tegnet nye aktier i BI Erhvervsejendomme A/S (”Selskabet”) og emissionen er fuldtegnet. Der blev tegnet for nominelt DKK 421.500.000 svarende til 4.215.000 stk. nye aktier til kurs 222,20.Da hele det tegnede aktiebeløb er indbetalt, har bestyrelsen dags dato truffet beslutning om at gennemføre kapitalforhøjelsen, som omtalt i selskabsmeddelelse af 21. januar 2021.Den totale aktiekapital udgør herefter DKK 2.868.100.000 fordelt på 28.681.000 stk. aktier à nominelt DKK 100.Opdaterede vedtægter for Selskabet er vedhæftet.Eventuelle spørgsmål kan rettes til BI Management A/S, Sundkrogsgade 7, 2100 København Ø, tlf. 77 30 90 00.Med venlig hilsenBI Management A/SMartin Fjordlund SmidtDirektørVedhæftet filVedtægter BI Erhvervsejendomme – 2021.01.21 clean

Today, the Board of Directors of SP Group A/S (SP Group) has resolved to increase the share buy-back programme authorised at the annual general meeting held on 29 April 2019.The share buy-back programme was announced in Company Announcement no. 37/2020 of 15 September 2020.SP Group holds 303,572 number of treasury shares of a nominal value of DKK 2 each corresponding to2.43 % of SP Group’s share capital as of 22 January 2020.The purpose of the share buy-back programme is to hedge the existing warrant programmes.The share buy-back programme runs from 15 September 2020 until 10 April 2021. The share buy-back programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014 as regards Market Abuse, the so-called Market Abuse Regulation that protects listed companies’ board and executive board...

Bestyrelsen i SP Group A/S (SP Group) har i dag besluttet at udvide tilbagekøbet af egne aktier i overensstemmelse med bemyndigelsen givet på den ordinære generalforsamling den 29. april 2019.Aktietilbagekøbsprogrammet blev offentliggjort i Selskabsmeddelelse nr. 37/2020 af den 15. september 2020.SP Group besidder 303.572 stk. egne aktier à nominelt DKK 2 svarende til 2,43 % af SP Groups aktiekapital pr. 22. januar 2020.Formålet med aktietilbagekøbsprogrammet er afdækning af eksisterende warrantprogrammer.Aktietilbagekøbet løber i perioden fra og med den 15. september 2020 til og med den 10. april 2021. Aktietilbagekøbsprogrammet er iværksat efter bestemmelserne i EU’s forordning nr. 596/2014 af den 16. april 2014 om markedsmisbrug, den såkaldte ’markedsmisbrugsforordning’, som værner børsnoterede selskabers bestyrelse og direktion...

(Oslo, 25 January 2021) Saga Pure ASA (Saga, OSE: SAGA) has as a cornerstone investor, committed to subscribe and be allocated shares for NOK 30 million in a private placement of new shares (the “Private Placement”) in CRC Holding B.V (“Pryme”). Following the Private Placement Saga will own approximately 4% of the company.“Over the last few years the world has come to truly understand the negative impacts plastic waste has on the ecosystems, and there is a strong need for innovative solutions to tackle the issue. One important pillar for handling the plastic issue is efficient recycling. Pryme has developed a solution which combines a high conversion rate along with large scale, both crucial to improve the economics of such operations, and by utilizing electricity for the process also enables a potentially zero overall carbon footprint,”...

NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19Paris, 25 January 2021, 8.30am CETAB Science SA (NYSE Euronext – FR0010557264 – AB) today announced the publication of preclinical study results with masitinib in COVID-19. Research led by scientists from the Institute of Human Virology (Guangzhou, China) has been published in the peer-reviewed journal mBIO (a journal of the American Society for Microbiology). The article, entitled ‘Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors’,[1] is freely accessible online from the mBio journal site https://mbio.asm.org/content/mbio/12/1/e02754-20.full.pdfThis article reports results...